MDT

99.9400.67%
EG

Elizabeth G. Nabel

Independent Director

Dr. Elizabeth G. Nabel, also known as Betsy, M.d., serves as Member of Scientific Advisory Board of Everly Well, Inc. from December 2019. She served as an Independent Director at Accolade, Inc. since June 2021 until April 08, 2025. She serves as Director at Valera LLC. Dr. Nabel serves as an Independent Director at Moderna, Inc. since March 10, 2021. She is Senior Advisor of OPKO Health Dr. Nabel serves as an Independent Director at Lyell Immunopharma, Inc. since April 2021. Dr. Nabel served as a Member of Strategic Advisory Board at Longwood Fund till December 2023. She was Chief Health and Medical Adviser at National Football League, Inc. since February 09, 2015. Dr. Nabel is Executive Vice President for Strategy at ModeX Therapeutics. Dr. Nabel had been the President of Harvard University-affiliated Brigham Health, which includes Brigham and Women’s Faulkner Hospital, Inc. since January 1, 2010 until March 1, 2021. Dr. Nabel has been the President of Harvard University-affiliated Brigham Health Brigham & Women’s Faulkner Hospital since January 1, 2010. Dr. Nabel is a cardiologist and distinguished biomedical researcher. She was the Scientific Director of Clinical Research in the National Heart, Lung and Blood Institute intramural program. She joined the NHLBI since 1999 until 2009 as the Institute’s Scientific Director of Clinical Research. Previously, Dr. Nabel served at the National Institutes of Health where she held a variety of roles, including Director of the National Heart, Lung and Blood Institute. She also began a program to investigate genetic variation among patients with vascular diseases. During her time at the NHLBI, Dr. Nabel has also served as the Chief of the Institute’s Vascular Biology Section, directing research on the molecular, cellular and genetic mechanisms that cause vascular disorders. She is also a Professor of Medicine at Harvard Medical School since 2010. She joined the faculty at the University of Michigan in 1987 as an Assistant Professor of Medicine and Director of the Cardiovascular Research Center in 1992, Professor of Internal Medicine and Physiology in 1994 and Director of the Division of Cardiology in 1997. While at the University of Michigan, she became known for her research in the field of vascular biology and molecular cardiology and for her gene transfer studies of the cardiovascular system. She had been Independent Non-Executive Director of Moderna, Inc. (formerly known as Moderna Therapeutics, Inc.) since December 15, 2015 until July 30, 2020. She serves as an Independent Director of Medtronic plc since 2014. She serves as a Member of the Board of Directors for the Keystone Symposium. She served as a Member of the Scientific Advisory Board at Moderna, Inc. and The Stanley J. Sarnoff Endowment for Cardiovascular Science. She served as a Director at National Heart, Lung and Blood Institute since February 2005 to 2009. She serves as the President of the North American Vascular Biology Organization and Councilor of the American Society of Clinical Investigation. She serves on international advisory including the Center for Transgene Technology and Gene Therapy and the Center for Molecular and Vascular Biology at the University of Leuven and the International Vascular Biology Organization. She served on American Heart Association including the Board of Directors, the Atherosclerosis, Thrombosis and Vascular Biology Council (Chair). She is an Editorial Board Member of The New England Journal of Medicine. She is a Reviewing Editor for Science and an Editorial Board Member of the Journal of Clinical Investigation. She also served as a Consulting Editor for Circulation, Circulation Research and Arteriosclerosis, Thrombosis and Vascular Biology. She serves as Member of the American Society of Clinical Investigation, the Association of American Physicians, the Institute of Medicine and the National Academy of Medicine of the National Academy of Sciences. An accomplished physician-scientist, Dr. Nabel work on the molecular genetics of cardiovascular diseases has produced 17 patents and more than 250 scientific publications. Her scientific contributions in cardiovascular gene transfer have developed molecular and cellular techniques, delineated that the pathophysiology of atherosclerosis and clarified the processes of cell division and growth of vascular smooth muscle cells in blood vessels. Studies on Hutchinson-Gilford Progeria Syndrome have characterized the vascular smooth muscle cell defect leading to premature heart attack and stroke. Her colleagues have elected her to the American Academy of the Arts and Sciences, the Institute of Medicine, the Association of American Physicians, the American Society of Clinical Investigation and she is a Fellow of the American Association for the Advancement of Science. Dr. Nabel is on the editorial Board for the New England Journal of Medicine and Science Translational Medicine. She is the editor of Scientific American Medicine. She is a Board-certified cardiologist who has taken care of many patients with cardiovascular disease, including women with heart disease. Dr. Nabel received her M.D. at Weill Cornell University Medical College before moving to Brigham and Women’s Faulkner Hospital and Harvard University where she completed an internship and residency in internal medicine and cardiovascular diseases at Brigham and Women’s Faulkner Hospital and Harvard University. She received her B.A. from St. Olaf College. In 2001, she received an honorary doctoral degree from the University of Leuven in Belgium.

Positions